List of Contributors vii
Preface ix
Part I: Nature of the condition
1 Non-alcoholic fatty liver disease: Hype or harm? 3
Stephen H. Caldwell and Curtis K. Argo
2 NAFLD: A worldwide problem 8
Joanna K. Dowman Geoffrey C. Farrell and Philip Newsome
3 Is insulin resistance the principal cause of NAFLD? 15
Ian F. Godsland Sanjeev Mehta Shareen Forbes Fabian Meienberg
Michael Yee Simon D. Taylor‐Robinson and Desmond G. Johnston
4 Paediatric NAFLD: A distinct disease with the propensity for
progressive fibrosis 29
Emer Fitzpatrick and Anil Dhawan
5 Non‐alcoholic fatty liver disease (NAFLD) as cause of
cryptogenic cirrhosis 36
Jay H. Lefkowitch
6 Is NAFLD different in absence of metabolic syndrome? 44
Yusuf Yilmaz
7 Occurrence of noncirrhotic HCC in NAFLD 50
Dawn M. Torres and Stephen A. Harrison
8 Fibrosis progression: Putative mechanisms and molecular
pathways 61
Wing‐Kin Syn and Anna Mae Diehl
9 When is it NAFLD and when is it ALD?: Can the histologic
evaluation of a liver biopsy guide the clinical evaluation? 72
Elizabeth M. Brunt and David E. Kleiner
10 Of men and microbes: Role of the intestinal microbiome in
non-alcoholic fatty liver disease 82
Muhammad Bilal Siddiqui Mohammed Shadab Siddiqui and Arun J.
Sanyal
11 Can genetic influence in non‐alcoholic fatty liver disease be
ignored? 91
Yang‐Lin Liu Christopher P. Day and Quentin M. Anstee
12 Is there a mechanistic link between hepatic steatosis and
cardiac rather than liver events? 103
Soo Lim
Part III: Diagnosis and Scoring
13 How to best diagnose NAFLD/NASH? 113
Vlad Ratziu
14 The clinical utility of noninvasive blood tests and
elastography 124
Emmanuel A. Tsochatzis and Massimo Pinzani
15 Are the guidelines—AASLD IASL EASL and BSG—of help in the
management of patients with NAFLD? 131
Cristina Margini and Jean‐François Dufour
16 Imaging methods for screening of hepatic steatosis 138
Hero K. Hussain
17 Are the advantages of obtaining a liver biopsy outweighed by
the disadvantages? 152
Jeremy F. L. Cobbold and Simon D. Taylor‐Robinson
18 Screening for NAFLD in high‐risk populations 161
Nader Lessan
Part IV: Value of treatment measures
19 Defining the role of metabolic physician 173
Nicholas Finer
20 Should physicians be prescribing or patients self‐medicating
with orlistat vitamin E vitamin D insulin sensitizers
pentoxifylline or coffee? 182
Haripriya Maddur and Brent A. Neuschwander‐Tetri
21 Effects of treatment of NAFLD on the metabolic syndrome
189
Hannele Yki‐Järvinen
22 What are the dangers as well as the true benefits of
bariatric surgery? 196
Andrew Jenkinson
23 Liver transplantation: What can it offer? 203
Roger Williams
Part V: What does the future hold?
24 Molecular antagonists leptin or other hormones in
supplementing environmental factors? 211
Jonathan M. Hazlehurst and Jeremy W. Tomlinson
25 What is the role of antifibrotic therapies in the current and
future management of NAFLD? 218
Natasha McDonald and Jonathan Fallowfield
26 Developmental programming of non‐alcoholic fatty liver
disease 226
Jiawei Li Paul Cordero and Jude A. Oben
Index 232
Professor Roger Williams CBE, runs the Institute of
Hepatology at UCL, and is a twice former president of EASL. He has
authored an incredible 2100 journal articles. Despite advancing
years, he is still actively involved in clinical research -- 340
articles in the past ten years, and analysis by ISI shows him to be
one of the most influential researchers in his field. The award of
a CBE for services to medicine recognised his major contribution to
the study of liver disorders over 25 years including leading the
team who performed the first ever UK liver transplant. He also
performed George Best's controversial liver transplant in 2002.
Prof Williams has had many awards, medals, honorary fellowships,
and in 2006 was included by HRH The Queen in a celebration at
Buckingham Palace to honour those who continue to contribute to
public service beyond the age of 65yrs. He was made a Fellow of
King's College London in 1992 and an Honorary Fellowship from UCL
was conferred on him in 2008, in recognition of his distinguished
career and outstanding service to UCL.
Professor Simon Taylor-Robinson joined the Department of Medicine at Imperial College London in 1997, having previously been Senior Registrar in Gastroenterology and Hepatology at Hammersmith Hospital. He was awarded the Sir Francis Avery Jones Gold Medal by the British Society of Gastroenterology in 1999 and the Young Investigator Award of the Liver Section of the European Gastroenterology Association in 1997. He is currently Director of the Imperial Clinical Research Facility at St Mary's Hospital, London.
![]() |
Ask a Question About this Product More... |
![]() |